We are developing the HeArTPAD™ cryo-ablation system which is intended to ablate the posterior wall of the left atrium epicardially. Successful animal testing was performed in late 2017 to demonstrate proof of concept.
To date we have secured $1.65 million in seed funding. For Series A we are seeking to raise a total investment of up to $10M to fund FDA 510(k) clearance of the HeArTPAD & Pericardial Access Platform for ablation of cardiac tissue